echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Gene therapy is expected to treat rare eye diseases

    Gene therapy is expected to treat rare eye diseases

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    To this end, the researchers screened 20 potential treatments in mouse models that have the same genetic defects as humans with retinitis pigmentosa.


    Experiments have shown that in three different mouse models, using a viral vector to deliver a gene called Txnip is the most effective way to treat this disease.


    The research team later proved that gene therapy to reduce oxidative stress and inflammation in mice, coupled with Txnip gene therapy, can provide additional protection for eye cells.


    "The next step is to test the safety of Txnip on animals other than mice, and then conduct human clinical trials.


    Related paper information: org/10.


    org/10.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.